SCHEMBL29800765

SCHEMBL29800765

O=S(=O)(Nc1cccc2cccnc12)c1cccc(-c2ccccc2)n1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 13/20 0.71
GLO1 Q04760 6/20 0.71
TDP1 Q9NUW8 7/20 0.65
NFKBIA P25963 2/20 0.65
AGTR1 P30556 2/20 0.65
G6PD P11413 1/20 0.65
METAP2 P50579 1/20 0.65
METAP1 P53582 1/20 0.65
PAX8 Q06710 1/20 0.65
ATM Q13315 1/20 0.65
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
RELA Q04206 1/20 0.56
HTT P42858 2/20 0.55
ALOX15 P16050 1/20 0.55
MITF O75030 1/20 0.54
S1PR4 O95977 1/20 0.54
ALDH1A1 P00352 1/20 0.54
LMNA P02545 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26964218 1.00 SLC40A1 (0.71) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL27214292 0.86 GLO1 (0.69) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL30925547 0.86 GLO1 (0.69) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL5477009 0.84 SLC40A1 (1.00) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL30925410 0.84 SLC40A1 (1.00) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL27214246 0.81 SLC40A1 (0.70) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL30925496 0.81 SLC40A1 (0.70) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL13485924 0.80 GLO1 (0.84) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL30925539 0.80 SLC40A1 (1.00) SLC40A1GLO1TDP1NFKBIAAGTR1
SCHEMBL11973694 0.80 SLC40A1 (1.00) SLC40A1GLO1TDP1NFKBIAAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 CN disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885GLO1 3779/4885TDP1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.